Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Theravance BiopharmaFRA:0TB -0.68%72 PS Ratio is 8.05 as of Jul. 30, 2026, which is 45% below its 10-year median of 14.74. GuruFocus rates FRA:0TB with a GF Score™ of 72/100 and a GF Value™ of €16.18 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 930 Biotechnology companies, Theravance Biopharma ranks better than 52.9% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Theravance Biopharma's share price is €14.60.
Theravance Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €1.81. Hence, Theravance Biopharma's PS Ratio for today is 8.05.
The historical rank and industry rank for Theravance Biopharma's PS Ratio or its related term are showing as below:
FRA:0TB'
s PS Ratio Range Over the Past 10 Years
Min: 6.14 Med: 14.74 Max: 110.4
Current: 7.99
During the past 13 years, Theravance Biopharma's highest PS Ratio was 110.40. The lowest was 6.14. And the median was 14.74.
FRA:0TB's PS Ratio is ranked better than 52.9% of 930
companies
in the Biotechnology industry
Industry Median: 8.89
vs FRA:0TB: 7.99
During the past 12 months, the average Revenue per Share Growth Rate of Theravance Biopharma was 59.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 44.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 14.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 5.30% per year.
During the past 13 years, Theravance Biopharma's highest 3-Year average Revenue per Share Growth Rate was 437.70% per year. The lowest was -32.60% per year. And the median was -3.20% per year.
Back to Basics: PS Ratio
Theravance Biopharma (FRA:0TB) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Theravance Biopharma PS Ratio Related Terms
Theravance Biopharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Theravance Biopharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Theravance Biopharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Theravance Biopharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Theravance Biopharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Theravance Biopharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Theravance Biopharma's Share Price of today is €14.60. Theravance Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.81.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Theravance Biopharma (FRA:0TB) has a PS Ratio of 8.05 as of Jul. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Theravance Biopharma and its competitors. This is 45% below median its historical median of 14.74. Over the past decade, Theravance Biopharma's PS Ratio has ranged from 6.14 to 110.40. According to the industry distribution chart, Theravance Biopharma ranks #438 out of 930 companies in the Biotechnology industry, placing it in the top 47.1%.
Is Theravance Biopharma's PS Ratio too high?
Theravance Biopharma's current PS Ratio of 8.05 is 45% below median its 10-year median of 14.74. Over the past 10 years, this metric has ranged from a low of 6.14 to a high of 110.40. The Biotechnology industry median PS Ratio is 8.89. Theravance Biopharma's value of 8.05 is 9.4% below this industry median. Based on the distribution chart, Theravance Biopharma ranks #438 out of 930 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Theravance Biopharma has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Theravance Biopharma's PS Ratio compare to ABUS and SANA?
According to the Biotechnology industry distribution chart, Theravance Biopharma ranks #438 out of 930 companies for PS Ratio. This puts Theravance Biopharma in the upper half of its industry. The industry median PS Ratio is 8.89. Theravance Biopharma's value of 8.05 is 9.4% below this benchmark. Historically, Theravance Biopharma's own PS Ratio has ranged from 6.14 to 110.40 over the past decade. While the company's 10-year median is 14.74 vs. the industry median of 8.89, Theravance Biopharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 8.89, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Theravance Biopharma's current PS Ratio of 8.05 is 9.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Theravance Biopharma and its competitors. For the Biotechnology industry, the median PS Ratio is 8.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Theravance Biopharma's current PS Ratio is 8.05, which is 45% below median its own 10-year median of 14.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theravance Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Theravance Biopharma (FRA:0TB) is currently considered Modestly Undervalued. The stock's GF Value™ is €16.18, compared to a current price of €14.60 — trading 9.8% below its estimated fair value. The current PS Ratio is 8.05, which is 45% below median its 10-year median of 14.74 and 9.4% below the Biotechnology industry median of 8.89. Theravance Biopharma's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Theravance Biopharma (FRA:0TB), the current PS Ratio is 8.05 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Theravance Biopharma (FRA:0TB) Overvalued in 2026?
Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued.
The current stock price of €14.60 is trading 9.8% below its estimated GF Value™ of €16.18.
GuruFocus considers Theravance Biopharma to be Modestly Undervalued.
Key valuation signals for FRA:0TB:
PS Ratio: 8.05 (45% below median its 10-year median of 14.74)
GF Value™: €16.18 vs. price of €14.60 (9.8% below fair value)
Industry Position: 9.4% below the Biotechnology median (#438 of 930)
No single metric tells the full story. See the FRA:0TB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
72GF Score
Get the complete analysis for FRA:0TB
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0TB has been successfully added to your 
